Applying next-generation sequencing to predict short progression-free survival in patients with advanced EGFR-mutant lung adenocarcinoma receiving epidermal growth factor receptor tyrosine kinase inhibitors.
Sign Up to like & getrecommendations! Published in 2025 at "Anti-cancer drugs"
DOI: 10.1097/cad.0000000000001762
Abstract: For patients with advanced EGFR-mutant lung adenocarcinoma, progression-free survival (PFS) is significantly improved by epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) medications. However, a subset of patients still experiences early disease progression. In this… read more here.
Keywords: egfr; lung; generation; patients advanced ... See more keywords
Abstract 2040: Virtual patient simulation improves first-line treatment selection in advanced EGFR-mutated NSCLC
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Research"
DOI: 10.1158/1538-7445.am2020-2040
Abstract: Background: Patients with advanced EGFR-mutated NSCLC benefit from treatment with EGFR TKIs. However, gaps in oncologists9 performance hamper their ability to integrate individualized treatments into the care of patients with this disease. This study was… read more here.
Keywords: egfr mutated; treatment; virtual patient; patient simulation ... See more keywords
EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR-mutated NSCLC: a network meta-analysis
Sign Up to like & getrecommendations! Published in 2024 at "BMC Cancer"
DOI: 10.1186/s12885-024-13168-8
Abstract: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and EGFR-TKI combination treatments have become the standard first-line treatments for EGFR-mutated non-small cell lung cancer (NSCLC) patients. However, the best option has yet to be… read more here.
Keywords: egfr; egfr tkis; egfr mutated; combination treatments ... See more keywords